This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Omic Smap Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Woo Chan Son: Innovator in Cancer Treatment
Introduction
Woo Chan Son is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating cancer. His innovative work has garnered attention for its potential impact on cancer therapies.
Latest Patents
Woo Chan Son holds a patent for a Quinazoline-2,4-diamine derivative and pharmaceutical composition for preventing or treating cancer. This compound exhibits a high inhibitory ability on euchromatic histone-lysine N-methyltransferase 2 (EHMT2). The invention includes a compound, a stereoisomer thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof, which can be effectively utilized in cancer treatment.
Career Highlights
Son is associated with Omic Smap Inc., where he continues to advance his research and development efforts. His work is characterized by a commitment to innovation and a focus on creating effective solutions for complex health issues.
Collaborations
Some of his notable coworkers include Jung Jin Hwang and Sang Eun Park, who contribute to the collaborative environment at Omic Smap Inc. Their combined expertise enhances the potential for groundbreaking discoveries in the pharmaceutical field.
Conclusion
Woo Chan Son's contributions to cancer treatment through his innovative patent highlight the importance of research and development in pharmaceuticals. His work exemplifies the potential of targeted therapies in improving patient outcomes.